4.7 Article

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

期刊

LEUKEMIA
卷 31, 期 10, 页码 2211-2218

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.86

关键词

-

资金

  1. National Cancer Institute of the National Institutes of Health [U10CA031946, U10CA033601, U10CA180821, U10CA180882, U10CA101140, U10CA180850, U10CA180866, U10CA18086, U10CA032291, U10CA035279, U10CA047545, U10CA059518, CA077658, CA016058, CA140158, CA180821, CA180882, CA196171, R35 CA197734, 5P30 CA016058]
  2. Coleman Leukemia Research Foundation
  3. D Warren Brown Foundation
  4. Pelotonia Fellowship Program

向作者/读者索取更多资源

Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML patients, and are used to denote specific disease entities in the World Health Organization classification of myeloid neoplasms and acute leukemia. However, large studies that integrate cytogenetic and comprehensive mutational information are scarce. We created a comprehensive oncoprint of mutations associated with recurrent cytogenetic findings by combining the information on mutational patterns of 80 cancer- and leukemia-associated genes with cytogenetic findings in 1603 adult patients with de novo AML. We show unique differences in the mutational profiles among major cytogenetic subsets, identify novel associations between recurrent cytogenetic abnormalities and both specific gene mutations and gene functional groups, and reveal differences in cytogenetic and mutational features between patients younger than 60 years and those aged 60 years or older. The identified associations between cytogenetic and molecular genetic data may help guide mutation testing in AML, and result in more focused application of targeted therapy in patients with de novo AML.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据